REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 years ago.
Eligibility
Sex
ALL
Min age
40 Years
Max age
70 Years
Healthy volunteers
Accepted
Inclusion Criteria:
A history of cancer \>5 y ago associated with potential cardiotoxicity from chemotherapy and/or radiotherapy (chiefly survivors of breast cancer, Hodgkin's lymphoma and prostate cancer).
Exclusion Criteria:
* Unable to provide written informed consent to participate in this study
* Known coronary artery disease at recruitment
* History of previous coronary artery disease
* Inability to acquire interpretable CT images
* Contraindications/Intolerance to or already taking statin therapy
* Oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial
Primary outcome measure(s)
Proportion of evaluated patients who should undergo CAD prevention — 3 years High clinical risk, or intermediate risk with CAC score \>0
Trial sites (2)
Facility
City
Region
Status
Tom Marwick
Hobart
Tasmania
Recruiting
Baker Heart and Diabetes Institute
Melbourne
Victoria
Recruiting
More Baker Heart and Diabetes Institute trials in Australia
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.